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Highlights  
 Limited data for bleeding risk scores are available with non-Vitamin K antagonist 
OACs(NOACs) in anticoagulated patients with atrial fibrillation(AF). 
 In this study contemporary bleeding risk scores(ATRIA, HAS-BLED, ORBIT) showed 
modest predictive values for major bleeding.  
 The HAS-BLED score classified least patients at low risk and achieved the highest 
clinical usefulness if applying a major bleeding intervention threshold of 2%, 
whereas benefit from other scores was only evident at higher thresholds. 
 
Abstract    
 
Background:  Various bleeding risk scores have been proposed to assess the risk of bleeding in 
patients with atrial fibrillation (AF) taking oral anticoagulants (OAC). Limited data are available 
with these scores, in users of non-Vitamin K antagonist OACs (NOACs). 
Methods: Using the Danish registries we evaluated and compared the risk classification properties 
of the HAS-BLED, ATRIA and ORBIT scores for predicting major bleeding in 57,930 atrial fibrillation 
patients (44.6% female; mean age 73.5 years, SD 11.4; mean CHA2DS2-VASc score 3.2, SD 1.8). 
Results.  At 1 year follow-up, C-statistics for ATRIA, HAS-BLED and ORBIT were approx. 0.59 with 
only minor differences between scores.  Both ATRIA and ORBIT categorized more patients as ‘low 
risk’ (both >83%, when compared to HAS-BLED, only 53%) and qualitatively, the ROC curves 
revealed higher sensitivity (62.8%) for HAS-BLED compared to ATRIA (29.7%) and ORBIT (37.1%).  
The clinical usefulness of scores was evaluated using decision curve analyses at a 1 year 
perspective. If the intervention threshold is low (<1.7%) the benefit is towards monitoring all 
patients. If preference is for a major bleeding risk threshold between 1.7-2.0%, most benefit was 
obtained by using HAS-BLED.  ORBIT and ATRIA score provided better benefit for thresholds 
between 2.0-6.0%. 
Conclusion:  This analysis of contemporary bleeding risk score stratification in a ‘real world’ NOAC 
users population with atrial fibrillation showed modest predictive values using C-statistics. The 
scores represent different risk thresholds with HAS-BLED classifying least patients at low risk and 
achieving the highest benefit if applying a major bleeding intervention threshold of approx. 2%, 
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whereas benefit from using either ATRIA score or ORBIT score was only evident using higher 
intervention thresholds. 
Key words:  bleeding, atrial fibrillation, risk stratification 
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Abbreviations:   
 
AF: Atrial fibrillation.  
 
OAC: Oral anticoagulants.  
 
VKA: Vitamin K antagonists.  
 
NOAC: non-VKA oral anticoagulants 
 
CHA2DS2-VASc score:  congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, 
stroke/transient ischemic attack/thromboembolism [doubled], vascular disease [prior myocardial 
infarction (MI), peripheral arterial disease (PAD), or aortic plaque], age 65-74 years, sex category 
[female] 
 
HAS-BLED:  Hypertension, Age, Stroke, Bleeding tendency/predisposition, Labile INRs, Elderly 
age/frailty, Drugs such as concomitant aspirin/NSAIDs or alcohol excess 
 
ATRIA: Anticoagulation and Risk Factors in Atrial Fibrillation 
 
ORBIT: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation  
Page 4 of 36
 5 
Introduction 
Stroke prevention is central to the management of patients with atrial fibrillation (AF), and 
effective stroke prevention requires use of oral anticoagulants (OAC)(1). The latter confers an 
excess risk of bleeding, and various clinical factors have been associated with bleeding risk(2). 
These clinical factors have been used to formulate bleeding risk scores, to assess the risk of 
bleeding in atrial fibrillation patients(2).   
Most bleeding risk scores have been derived and/or validated in patients taking Vitamin K 
antagonists (VKA, eg. warfarin) as the OAC(2).  More recently, the non-VKA oral anticoagulants 
(NOAC) have been increasingly used for stroke prevention, but limited data are available on the 
comparative predictive and clinical value of various bleeding risk scores, specifically in NOAC users.   
Of the various bleeding risk scores, the HAS-BLED(3) score has been used in various guidelines(4), 
but more recently the ATRIA(5) and ORBIT(6) scores have been proposed as alternative scores that 
appear applicable to the NOAC era. All scores assign integer valued points to a range of risk factors 
and use the total points to classify into risk strata (low, intermediate, high risk). 
Our objective was to compare the predictive value of the stratification schemes proposed by HAS-
BLED, ATRIA, and ORBIT bleeding scores in patients with  atrial fibrillation treated with NOACs in a 
nationwide cohort study, using the Danish registries. 
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Methods 
This study included data from three Danish nationwide databases, which may be linked according 
to Danish legislation for research purposes. Linkage is enabled by the unique identification 
number that all Danish citizens hold and is being used throughout all nationwide databases. We 
used: (i) the Danish National Prescription Registry(7) which holds detailed information on every 
prescription withdrawal since 1994; (ii) the Danish National Patient Register(8) established in 
1977, which includes data for >99% of somatic hospital admissions; and (iii) the Danish Civil 
Registration System(9) with demographic information.  Study population is detailed in the 
Supplementary Material. 
To establish an OAC naïve cohort, we excluded patients with prior experience of any OAC inclusive 
doses approved for other indications within one year. Eventually, we excluded patients with prior 
hospital diagnoses indicating valvular atrial fibrillation (mitral stenosis or mechanical heart valves) 
or venous thromboembolism (pulmonary embolism or deep venous thromboembolism). This 
population formed the study cohort for the analyses.  
Endpoints and baseline variable definitions  
Clinical endpoints were extracted from hospital discharge codes in the Danish National Patient 
Register using the 10th Revision of ICD codes (see Supplementary Table 1 for specific codes) with 
follow-up until April 30, 2016.  The scores were evaluated on the following bleeding events: 
intracranial, gastro-intestinal, traumatic intracranial and clinically relevant non-major bleeding 
reported in total as ‘any bleeding’ (see supplementary Table 1 for ICD-10 discharge codes). 
Primary and secondary inpatient hospital discharge codes were used for endpoint evaluation; to 
ensure higher validity of the measured outcomes non-emergency ward and outpatient codes were 
not assessed. 
Patient’s comorbidities and co-medications at treatment initiation (as listed in Table 1) were 
ascertained from the Danish National Patient Registry and the Danish National Prescription 
Registry (for code definitions, see Supplementary Table 1). Baseline medication was ascertained 
by the presence of at least one prescription within 365 days prior to study entry, where as 
comorbidity based on hospital discharge codes included information from hospitalizations and 
ambulatory visits, but excluding diagnoses coded in emergency wards. 
Bleeding scores 
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Based on patient baseline comorbidity and medication, bleeding risk was ascertained using the 
risk classifications defined by the HAS-BLED(3) , ATRIA(5), and ORBIT(6) bleeding risk scores (see 
score definitions in Supplementary Table 2). Due to non-availability of data in the national 
registers, labile INR in the HAS-BLED could not be evaluated, but this criterion was not relevant as 
all patients were OAC naïve at inclusion and initiated a NOAC treatment.  
Renal dysfunction was not uniformly defined in the three scores: in HAS-BLED it is defined as 
presence of chronic dialysis, renal transplantation, or serum creatinine ≥ 200 m mol/L; in ATRIA: 
glomerular filtration rate <30 ml/min or dialysis dependent; in ORBIT as insufficient kidney 
function (eGFR < 60 mg/dL/1.73 m2). We ascertained renal dysfunction as the presence of prior 
hospital discharge codes indicating insufficient renal function (see Supplementary Table 1; 
hypertensive kidney disease, acute or chronic glomerulonephritis, hematuria, nephrosis, 
nephropaty, nephritis, acute or chronic renal insufficiency, polycystic kidney disease). Thus, we 
applied a generic definition and did not distinguish between bleeding score definitions of renal 
dysfunction in our study. 
The ATRIA and ORBIT scores assigned points for anemia, and the ORBIT score further included 
information regarding abnormal haemoglobin (<13 mg/dL for males and <12 mg/dL for females) or 
haematocrit (<40% for males and <36% for females). In the present evaluation, we only included 
hospital discharge information regarding anemia due to non-availability of laboratory data.  
The HAS-BLED score assigns risk scores in the range 0 to 8 and the following risk strata 
categorization was suggested(3): low risk as scores 0-2 and high risk for scores ≥3. The ATRIA score 
assigns risk in the range 0 to 10 with the risk strata classification(10): low risk as scores 0-3 and 
intermediate/high risk for scores ≥4. The ORBIT score assigns risk in the range 0 to 7 and with risk 
strata classification(6): low risk to scores 0-2 and intermediate/high risk for scores ≥3.  
In the present study all scores risk classification were considered as dichotomized to low risk vs 
intermediate/high risk.  
Statistical analysis 
Detailed statistical methods are provided in the Supplementary Materials. In brief, risk strata were 
compared using Cox-proportional hazards regression. Discrimination based on the dichotomized 
risk classification was evaluated using C-statistics based on time-dependent areas under the ROC-
curves, both acknowledging survival data and competing risk for death(11).  The net benefit (NB) 
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for assigning intermediate/high risk was evaluated by decision curve analysis (12)(13). The risk 
threshold is the anticipated treatment risk at which the utility of treatment equals the cost of 
avoiding treatment.   
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Results 
 
A total number of 57,930 OAC naïve non-valvular atrial fibrillation patients were identified and 
included in this study [Supplemental figure 1]. Females accounted for 44.6% and the mean age 
(SD) was 73.5 (11.4) years. The mean CHA2DS2-VASc score for stroke risk was 3.2 (1.8), with 
hypertension being the most prevalent risk factor (59.0%). Further population baseline 
characteristics are summarised in Table 1. 
 
The distributions of the individual bleeding score levels are shown in Table 2, with the mean 
scores ranging from 1.4 (ORBIT) to 2.4 (HAS-BLED) with ATRIA being intermediate with mean 2.0.  
The ATRIA and ORBIT scores categorized 12.7% and 16.4% of the study population, respectively, as 
being at intermediate/high bleeding risk, whereas this proportion using HAS-BLED was 46.8%. 
 
Event rates in relation to bleeding risk scores 
The overall event rate (per 100 person-years) of the combined bleeding endpoint was 2.41 at 1 
year of follow-up.  The 1-year bleeding rates ranged between 0.47 and approximately 11.3 across 
individual score levels with the lowest rate identified by HAS-BLED score level 0. The score level 0 
groups of ATRIA and ORBIT both had bleeding rates of 0.80-0.90 per 100 person-years (Table 2). 
All scores showed positive trends for increased bleeding rates with increasing scores. The crude 1-
year bleeding rates per 100 person-years for patients categorized as intermediate/high risk were 
3.30 (HAS-BLED), and by combining intermediate and high-risk groups in ORBIT: 5.84, and ATRIA: 
6.1 (ATRIA). On score level, the lowest rates in the intermediate/high risk categories were 2.75 
(HAS-BLED), 4.72 (ORBIT), and 5.30 (ATRIA). The low risk groups represented rates up to 2.93 
(ORBIT) per 100 person-years. See Supplementary Table 3 for the corresponding rates for 2.5 
years follow-up.   
 
The low risk categories had bleeding risk at 1-year follow-up of below 1.9%, whereas the 
intermediate/high risk category in HAS-BLED conferred an average risk of 3.0%, while for ORBIT 
intermediate risk was 4.2% and for ATRIA, 4.7%, in high risk groups the risk was about 5.6% based 
on cumulative incidence (Figure 1). The rate differences between the low risk and intermediate 
risk groups corresponded to hazard rate ratios (HRs) with low risk group as reference: HAS-BLED 
with HR 1.99 (95% CI 1.77-2.23); ATRIA with HR 2.73 (95% CI 2.29-3.25); and ORBIT with HR 2.61 
(95% CI 2.22-3.07), noting that HAS-BLED does not distinguish between intermediate and high risk. 
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HRs were generally attenuated when evaluated at 2.5 years follow-up (see Supplementary figure 
2).  
 
Predictive value of bleeding scores 
In terms of discrimination, Table 3 shows C-statistics at 1 year follow-up for ATRIA as 0.59 (95% CI 
0.57-0.60), HAS-BLED 0.58 (95% CI 0.57-0.59), and ORBIT 0.61 (95% CI 0.59-0.62), with ORBIT 
displaying statistically significant difference from both ATRIA and HAS-BLED (p<0.001). At the 2.5 
years follow-up, comparable statistics were obtained (Supplementary figure 3).  
 
Qualitatively, HAS-BLED show higher sensitivity (62.8%) for categorizing intermediate/high risk 
compared to ATRIA (29.7%) and ORBIT (37.1%) at the expense of reduced specificity for 
categorization as intermediate/high risk (specificity: HAS-BLED 53.5%; ATRIA 87.6%; ORBIT 84.0%). 
In this population, the positive predictive values ranged from 3.0% (HAS-BLED) to 5.2% (ATRIA, 
ORBIT), and with all negative predictive values above 98.2% at 1 year (Table 3). After 2.5 years, the 
PPVs overall increased by approx. 70% (HAS-BLED: 5.4%, ORBIT: 8.8%, ATRIA: 9.2%) whereas NPV 
was essentially unchanged (Supplementary Table 4). 
 
Decision curve analysis 
The clinical usefulness was evaluated by use of decision curves, as presented in Figure 3. The 
potential benefit of being guided by the score classification is linked to the assumed threshold for 
intervention, which in this study should be considered as the patient being subjected to more 
extensive monitoring to avoid bleeding incidences. At a 1 year perspective, and if the threshold is 
low (<1.7%), the benefit is towards monitoring all patients. If preference is to thresholds ranging 
1.7% and 2.0%, most benefit was obtained by using the HAS-BLED score as guidance.  The ORBIT or 
ATRIA scores provided better benefit for thresholds between 2% and 6%.  
If the preferred threshold for intervention is above 6%, none of the tested scores will have positive 
benefit, since the intermediate/high risk categories identified as a whole have an incidence of 
bleeding at maximum of 6% (Figure 3).  
The relations between the scores were maintained at 2.5 years of follow-up although the 
thresholds were shifted upwards (Supplementary Figure 4). 
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Discussion 
Our principal finding is that at 1 year follow-up, predictive values (using AUC/C-statistics) for 
ATRIA, HAS-BLED and ORBIT risk score classifications were broadly similar and performances were 
modest.  Second, both ATRIA and ORBIT categorized more patients as ‘low risk’ and qualitatively, 
there was higher sensitivity on the expense of specificity and positive predictive value for HAS-
BLED compared to ATRIA and ORBIT. Third, decision curve analyses at a 1 year perspective shows 
that if preference is for a major bleeding risk threshold between 1.7-2.0%, most benefit was 
obtained by using HAS-BLED, whereas the ORBIT and ATRIA scores provided better benefit for 
thresholds between 2.6-6.0%.  As far as we are aware this is the largest “real world” analysis of bleeding 
risk scores in atrial fibrillation patients who are NOAC users, based on an entire nationwide cohort (and 
not selective insurance provider claims data). 
The use of bleeding risk scores has been subject to misinterpretation and misuse(14). Bleeding risk 
assessment should be part of the holistic management of atrial fibrillation patients being started 
on antithrombotic therapy.  While modifiable bleeding risk factors should be addressed in all 
anticoagulated patients, a high bleeding risk score per se should be a help to treating physicians by 
‘flagging up’ those patients at risk of bleeding for more regular review and follow-up (which is 
relevant these days in the era of Electronic Health Records (EHR) (14)).    
Since many bleeding risk factors are potentially modifiable, for example, (uncontrolled) 
hypertension, concomitant use of aspirin or NSAIDs, alcohol excess, etc – a useful bleeding risk 
score should draw attention to these reversible factors, so they can be addressed(2). In a VKA 
user, labile INR (as reflected by poor time in therapeutic range, TTR) is a powerful determinant of 
bleeding (and thromboembolism) risk(15), but this criterion in HAS-BLED is not applicable in NOAC 
users. Bleeding risk assessment is also a dynamic process, and should be applicable at all stages of 
the patient management pathway: when first diagnosed on no antithrombotic therapy (or aspirin) 
and following OAC initiation. A high bleeding risk score is not a reason to withhold OAC, as the net 
clinical benefit balancing ischaemic stroke reduction against serious bleeding is even greater in 
such patients(16).  
The HAS-BLED score was initially derived from the EuroHeart survey atrial fibrillation population 
on VKA, and has been subsequently validated in patient cohorts who are not taking any 
antithrombotic therapy, aspirin and OAC (whether VKA or non-VKA users), as well as in atrial 
fibrillation and non- atrial fibrillation cohorts in trial and non-trial (ie. ‘real world’) patients 
Page 11 of 36
 12 
populations(3) (17–19).   The ATRIA bleeding score was derived from the ATRIA community cohort 
amongst VKA users, and validated in the ROCKET-AF trial population, while the ORBIT score was 
derived from the ORBIT registry, where most were VKA users(5) (6).  In the derivation studies(3) 
(5) (6), the rates for low risk were in the derivation/validation cohorts at maximum 3.20/1.88 
(respectively) for the HAS-BLED score, 2.9 in ORBIT (missing validation cohort), and 0.88/1.27 in 
ATRIA derivation/validation cohorts. The rates for high-risk groups were at least 19.51/3.74 in 
HAS-BLED derivation/validation cohorts, 6.8 in ORBIT derivation cohort, and 6.34/4.18 in ATRIA 
derivation/validation cohorts. Highlighting, that these studies did not apply comparable risk 
thresholds when assigning risk classification.  Withholding these classifications, as in the present 
study, recent analyses amongst VKA users clearly show that ATRIA and ORBIT would have a 
significantly poorer predictive value for clinically relevant or major bleeding or ICH compared to 
HAS-BLED, by not considering the labile INR criterion(20, 21). 
In correspondence with the score comparison based on the AMADEUS trials(21) ATRIA and ORBIT 
categorized >85% as ‘low risk’ which may lead to non-alerts from EHR, and patients not ‘flagged 
up’ for review and follow-up. The lower risk threshold of HAS-BLED thus on the other hand lead to 
higher sensitivity on the expense of a lower specificity and positive predictive value.  As shown in 
our decision curve analysis, if the preference is for a major bleeding risk intervention threshold 
between 1.3-1.8%, most benefit was obtained by using the HAS-BLED score, while ORBIT provided 
better benefit for thresholds between 1.8-3%; and ATRIA at >3%.  In comparison a stroke 
treatment threshold for OAC has been proposed for approximately 1.0-1.7%/year(22), which was 
based on quality-adjusted life-year analysis. A similar bleeding risk threshold approach to aid 
decision-making could prove useful for treating physicians. Yet, stroke and bleeding risk 
stratification may not easily translate into individual patient evaluation, and decisions on life-long 
antithrombotic treatment should cover the patient as a whole, and not be confined to risk 
estimates from population-based studies. Nevertheless, our decision curve analysis may hint a 
preferred score on the expense on another in case an appropriate threshold can be agreed upon.  
In accordance, the recent European Society of Cardiology (ESC) guidelines do not recommend a 
specific bleeding risk score, but tabulates a long list of modifiable, non-modifiable and biomarker-
related bleeding risk factors(23).  As highlighted above, this precludes use of a simple risk score to 
aid follow-up decisions or to help flag up patients at risk for more regular review and follow-up.  
While emphasis on reversible bleeding risk factors are paramount, the suggestion of a biomarker-
based bleeding predictor is less useful given that many biomarkers are predictive of bleeding as 
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well as stroke, myocardial infarction, heart failure, sudden death etc., which could lead to 
confusion amongst clinicians over which endpoint to focus on.  In addition, one may question the 
generalizability of biomarker predictions of bleeding, since these studies were based on highly 
selected anticoagulated cohorts in the NOAC randomized trials, where bloods tests are baseline 
were used for predicting events over many years of follow-up (14)(24–26). Indeed, in a real world 
anticoagulated atrial fibrillation cohort, the HAS-BLED score performed better than a biomarker 
based score in predicting major bleeding (27).  Hence, clinical management of atrial fibrillation 
patients would be best served with a simple clinical bleeding risk score that is used appropriately.  
 
Study limitations 
The main limitations pertain to the observational nature of our study with a potential of low 
generalizability due to possible bias from selective prescribing. Specifically, we only included users 
of NOACs, and atrial fibrillation patients deemed inappropriate for this treatment were not 
investigated (e.g. end-stage renal kidney disease). The scores differ in some details on the 
definition of specific risk factors, which could not be ascertained due to lack of laboratory data; 
these may influence the score distribution.  Observational cohorts have a risk of misclassification 
but the outcomes ascertained have been previously validated with a high positive predictive value 
(e.g. 97-100% for ischemic stroke)(28).  In addition, endpoints were not adjudicated (unlike a trial 
cohort) and post mortems were not mandated; therefore, some severe bleeding episodes with 
fatal consequences may not have been fully captured in the coding applied for endpoint analysis. 
Patient adherence to the NOACs and prescribing practices were not considered. Our data apply to 
a predominantly white European population, and differential efficacy and safety benefits may be 
evident between Asians and non-Asians (29, 30).    
 
Conclusions  
This analysis of contemporary bleeding risk scores in a ‘real world’ NOAC user population with 
atrial fibrillation showed modest predictive performance in terms of C-statistics. The scores 
represent different risk thresholds with HAS-BLED classifying least patients at low risk and 
achieving the highest benefit if applying a major bleeding intervention threshold of approx. 2.0%, 
whereas benefit from using either ATRIA score or ORBIT score was evident using higher 
intervention thresholds. 
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Figure 1: Cumulative incidence curves for outcomes at up to 1 years follow-up for each risk 
classification strata and score and with hazard rate ratio (HR (95%CI)) for intermediate/high risk 
vs low risk group within risk classification score.
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Figure 2: Calibration plots for risk scores and risk strata (low, intermediate high risk) of any bleeding at 1 years follow-up. 
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Figure 3 Decision curves curve analysis plots for score risk classification (low, intermediate, high risk) of any bleeding at 1 year follow-up. 
Page 20 of 36
21 
 
Table 1. Participant characteristics at treatment initiation.  
 NOAC 
N=57,930 
Females 44.6 (25,839) 
Age, mean (sd)  73.5 (11.4) 
Prior AF diagnosis 65.1 (37,706) 
CHA2DS2-VASc, mean (sd) 3.2 (1.8) 
Heart failure or LVD 22.5 (13,053) 
Diabetes mellitus 15.2 (8,798) 
Vascular diseases 16.2 (9,404) 
Hypertension 59.0 (34,153) 
CPD 13.3 (7,704) 
Prior bleeding 14.2 (8,242) 
Kidney diseases 3.4 (1,968) 
Aspirin# 39.1 (22,638) 
Beta-blocker# 37.8.7 (21,891) 
NSAIDs# 22.4 (12,949) 
Loop diuretics# 18.0 (10,446) 
 
   
Abbreviations: sd = Between-subjects standard deviation, CPD= Chronic pulmonary disease, 
Kidney diseases: Renal dysfunction/kidney transplant/dialysis, NSAIDs = Non-steroidal anti-
inflammatory drugs 
#At least one prescription within 1 year prior to NOAC initiation. 
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Table 2. Distribution of individual baseline score levels and risk classification and crude event rates per 100 person-years (number 
of events) at 1 year follow-up of any bleeding according to bleeding score level and risk classification.   
 Baseline score distribution  Crude 1 year event bleeding event rates 
Score level ATRIA   
% (N) 
HAS-BLED  
% (N) 
ORBIT   
% (N) 
ATRIA  
Rate (N) 
HAS-BLED  
Rate (N) 
ORBIT  
Rate (N) 
0 21.0 (12,158) 4.8 (2,770) 28.0 (16,233) 0.81 (91) 0.47 (12) 0.91 (135) 
1 26.5 (15,372) 18.2 (10,567) 35.2 (19,701) 1.53 (215) 1.27 (121) 1.85 (325) 
2 15.9 (9,208) 30.2 (17,497) 21.6 (12,517) 2.87 (229) 2.08 (324) 2.93 (316) 
3 23.8 (13,805) 29.9 (17,309) 7.8 (4,508) 2.80 (332) 2.75 (418) 4.72 (180) 
4 5.6 (3,263) 13.6 (7,877) 6.1 (3,520) 5.30 (146) 3.86 (260) 6.52 (188) 
5 2.0 (1,151) 2.9 (1,708) 1.4 (829) 6.56 (60) 5.65 (80) 7.37 (48) 
6 3.3 (1,888) 0.3 (202) 1.1 (622) 6.04 (90) 11.33 (18) 8.59 (41) 
7 1.3 (769) - - 8.27 (50) - - 
8 0.1 (83) - - 8.03 (5) - - 
9-10 0.4 (233) - - 8.77 (15) - - 
Mean (sd) 2.0 (1.7) 2.4 (1.2) 1.4 (1.3)    
Score risk classification       
Low risk  87.2 (50,543) 53.2 (30.834) 83.6 (48,451) 1.92 (867) 1.66 (457) 1.79 (776) 
Intermediate  5.6 (3,263) 46.8 (27,096) 7.8 (4,508) 5.30 (146) 3.30 (776) 4.72 (180) 
High risk 7.1 (4,124) NA 8.6 (4,971) 6.78 (220) NA 6.91 (277) 
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Table 3.  Discriminative statistics for risk scores using published categorization (low, intermediate, high risk), overall by C-
statistics, and by risk thresholds in terms of sensitivity, specificity, negative (NPV) and positive predictive values (PPV) for any 
bleeding at 1 year follow-up. 
Risk score C-statistics Threshold Sensitivity Specificity NPV PPV  
ATRIA 0.59 (0.57-0.60) Intermediate / high risk 29.7 87.6 98.2 5.2 
  High risk 17.9 93.1 98.0 5.6 
HAS-BLED 0.58 (0.57-0.59) Intermediate / high risk 62.8 53.5 98.4 3.0 
  High risk - - - - 
ORBIT 0.61 (0.59-0.62) Intermediate / high risk 37.1 84.0 98.3 5.0 
  High risk 22.5 91.8 98.1 5.8 
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SUPPLEMENTARY MATERIAL 
 
Detailed statistical methods 
Study population 
The study was based on new users of NOAC with no hospital information for treatment for other indications than  atrial fibrillation. 
We identified patients with first-time purchases of each NOAC approved for atrial fibrillation from their respective dates of 
approval for atrial fibrillation: apixaban (December 10, 2012), dabigatran (August 10, 2011), rivaroxaban (February 1, 2012). 
Patient inclusion was terminated by February 28, 2016.   
 
Statistical analyses 
For each score, crude event rates were calculated as number of events divided by person years for each score level and for each 
risk classification strata.  The event risk up to 2.5 years follow-up was depicted in terms of cumulative incidence functions based on 
the Aalen-Johansen estimator acknowledging competing risk for death. Risk strata were compared using Cox-proportional hazards 
regression. 
To visualize the predictive performance for the three scores from their respective derivation cohort and the data applied in current 
study, the points from each scoring system were plotted against the event rates of bleeding. Discrimination based on the 
dichotomized risk classification was evaluated using C-statistics based on time-dependent areas under the ROC-curves, both 
acknowledging survival data and competing risk for death(11). Also negative and positive predicted values were reported. 
Confidence intervals for reported measures were based on 500 bootstrap samples. 
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The net benefit (NB) for assigning intermediate/high risk was evaluated by decision curve analysis by weighing the proportion of 
true positives (TP) against the false positives (FP) as (TP - w * FP)/N, with “w” as penalty for false positive(12). In decision curve 
analysis, w is defined as p/(1-p), where p is a selected risk threshold for “intervention”(13). The risk threshold is the anticipated 
treatment risk at which the utility of treatment equals the cost of avoiding treatment. Under this definition it can be derived that 
p/(1-p) will represent the cost of an unnecessary treatment of the false positive patient, irrespective of the scale of the utility, yet 
acknowledging the utility difference between treatment and no-treatment of the true positive patient. The two simplest rules are 
either treat all and treat none. In the treat none case this will result in NB=0 as no one is considered positive (as TP=FP=0). Under 
the treat all rule NB depend on the anticipated risk threshold. If there is correspondence between the rule and the threshold, i.e. 
p=0, then NB=TP/N, which is the prevalence of positives. If the threshold is higher, p>0, then NB decrease linearly and reach zero at 
p=TP/(FP+FP), which under the treat all rule again corresponds to the prevalence of positives, as all negatives are classified as false 
positives. For a dichotomous decision rule (low risk vs high risk) NB will coincide with the treat all rule up to the point where risk 
threshold exceeds the proportion of true positives plow =TPlow /(FPlow +FPlow) in the low risk group. A lower risk threshold (p<plow) 
would correspond to classifying all patients as positives. A higher risk threshold (p>plow) calls for the use of the decision rule to 
focus on the high risk population. If the decision rule is sensible, one should expect that the number of true positives will be 
materially unchanged, whereas the number of false positives should be substantially reduced. In effect, this ought to result in a 
higher NB than for the treat all strategy. As the threshold p increases, NB will diminish and reach NB=0 at phigh =TPhigh /(FPhigh 
+FPhigh) the proportion of true positives in the high risk group.  In the setting of survival data the proportions are replaced by the 
corresponding risks, e.g. estimated by Aalen-Johansen cumulative incidence functions.  
Stata/MP version 14 and R version 3.1.1 was used for the statistical analysis.  A two-sided P value <0.05 was considered 
statistically significant. 
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Supplementary figure 1 Flowchart of study population selection 
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Supplementary figure 2 Cumulative incidence curves for outcomes at up to 2.5 years 
follow-up for each risk classification strata and score and with hazard rate ratio for 
intermediate/high risk vs low risk group within risk classification score. 
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Supplementary figure 3 ROC curves for score risk classification (low, 
intermediate/high risk) discrimination of any bleeding at 2.5 years follow-up  
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Supplementary figure 4 Decision curves curve analysis plots for score risk 
classification (low, intermediate/high risk) of any bleeding at 2.5 years follow-up. 
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Supplementary Table 1 
Definitions on comorbidity and concomitant medication according to ICD-10 codes and ATC-codes. Conditions marked with † was used in the 
calculation of the CHA2DS2-VASc score. Conditions marked with # was used in the calculation of the HAS-BLED score. 
 
International Classification of 
Diseases 10th revision (ICD-10) 
code 
Anatomical Therapeutic 
Chemical (ATC) code 
Condition   
  †Congestive heart failure I110 I130 I132 I420 I50 CO3C and C09 
  †Left ventricular dysfunction I501 I509  
  †#Hypertension  See specified definition* 
  †Diabetes mellitus E100 E101 E109 E110 E111 
E119 
A10 
  †#Ischemic stroke I63 I64  
  †Systemic embolism I74  
  †#Transient ischemic disease G45  
  †Aortic plaque I70.0  
  †Peripheral arterial disease  I702-I709 I71 I739  
  †Myocardial infarction I21-I23  
  #Moderate/severe renal disease  I12 I13 N00 N01 N02 N03 N04 
N05 N07 N11 N14 N17 N18 N19 
Q61 
 
  #Moderate/Severe liver disease  B150 B160 B162 B190 K704 K72 
K766 I85 
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  Cancer  C  
  Chronic pulmonary disease  J40 J41 J42 J43 J44 J45 J46 J47 
J60 J61 J62 J63 J64 J65 J67 J684 
J701 J703 J841 J920 J921 J982 
J983 
 
  Mitral stenosis  I05  
  Mechanical heart valve  Z952 Z953 Z954  
  #Haemorrhagic stroke – intracranial 
       bleeding 
I60 I61 I62  
  #Extracranial or unclassified major 
       bleeding  
D62 J942 H113 H356 H431 N02 
R04 R31 R58 
 
  #Gastrointestinal bleeding  K250 K252 K254 K260 K262 
K264 K270 K272 K274 K280 
K282 K290 K291 
 
  #Traumatic intercranial bleeding  S063C S064 S065 S066  
  #Alcohol E224 E529A F10 G312 G621 
G721 I426 K292 K70 K860 
L278A O354 T51 Z714 Z721 
 
  Pulmonary embolism  I26  
  Deep venous thromboembolism  I801 I802 I803 I808 I809 I819 
I636 I676 I822 I823 I829 
 
  Atrial fibrillation I48   
Medication   
  Apixaban 
  Dabigatran 
 B01AF02 
B01AE07 
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  Rivaroxaban B01AF01 
  Warfarin  B01AA03 
  Phenprocoumon  B01AA04 
  #Aspirin  B01AC06 
  #Clopidogrel  B01AC04 
  Beta-blockers  C07 
  Statins   C10 
  #NSAIDs   M01A 
  Loop diuretics  C03C 
  ACE/ARB inhibitors  C09 
NSAIDs: Non Steroidal Anti Inflammatory Drugs. 
* We identified subjects with hypertension from combination treatment with at least two of the following classes of 
antihypertensive drugs: 
I· Alpha adrenergic blockers (C02A, C02B, C02C) 
II· Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, C09XA52) 
III· Vasodilators (C02DB, C02DD, C02DG, C04, C05)  
IV· Beta blockers (C07) 
V· Calcium channel blockers (C07F, C08, C09BB, C09DB) 
VI· Renin-angiotensin system inhibitors (C09) 
As well as combination drugs: C07B, C09BB04, C09DA, C09DB, C09DX01, C09DX04  
 
Danish hospital discharge codes have been validated in extensively in the literature, please consult Schmidt et al. Clin Epid 
2015;7:449-90 for a comprehensive overview and Sundbøll et al. BMJ Open 2016;6(11). 
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Supplementary table 2.  Bleeding Score definitions 
1. HAS-BLED 
Component  Prefix   Weight 
Hypertension  (Alfa+NonLoop+Vaso+Beta+Calcium+Renin)>1 
 or combination drug   1 
Renal Disease  Renal   1 
Liver Disease  Liver   1 
Stroke  Istroke or TIA   1 
Bleeding  IBleed or MBleed3 or Gbleed2 or TIbleed   1 
Age  Age>=65   1 
Drugs  Aspirin or clopidogrel or NSAID   1 
Alcohol  Alco   1 
Risk classification Low: 0-3 Intermediate/High 4-8 
 
2. ATRIA 
Component  Prefix   Weight 
Anemia  Anemia   3 
eGFR<30 or dialysis  Renal   3 
Age  Age>=75   2 
Bleeding  IBleed or MBleed3 or Gbleed2 or TIbleed   1 
Hypertension (Alfa+NonLoop+Vaso+Beta+Calcium+Renin)>1 
or combination drug   1 
Risk classification Low: 0-3 Intermediate: 4 High 5-10 
 
3. ORBIT 
Component  Prefix   Weight 
Age  Age>=75   1 
Anemia/red.haem  Anemia   2 
Bleeding  IBleed or MBleed3 or Gbleed2 or TIbleed  2 
eGFR<60mL/min/1.73m2  Renal   1 
Antiplatelet  Aspirin or thienopyridines   1 
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Risk classification Low: 0-2 Intermediate: 3 High 4-7 
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Supplementary Table 3. Crude event rates per 100 person-years (number of events) at 2.5 years follow-up of any bleeding 
according to bleeding score level and risk classification.   
 2.5 year 
Score level ATRIA  
Rate (N) 
HAS-BLED 
Rate (N) 
ORBIT  
Rate (N) 
0 0.77 (170) 0.42 (21) 0.82 (238) 
1 1.23 (347) 1.03 (189) 1.59 (548) 
2 2.42 (363) 1.79 (539) 2.49 (508) 
3 2.42 (538) 2.18 (642) 3.78 (271) 
4 4.47 (230) 3.24 (413) 4.97 (260) 
5 4.97 (81) 4.36 (114) 5.77 (66) 
6 4.55 (121) 10.22 (28) 6.53 (55) 
7 6.58 (71) - - 
8 6.11 (6) - - 
9-10  6.94 (19) - - 
Score risk 
classification 
   
Low risk  1.62 (1,418) 1.40 (749) 1.54 (1294) 
Intermediate/high risk  4.85 (528) 2.66 (1197) 4.53 (652) 
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Supplementary table 4.  Discriminative statistics for risk scores using published categorization (low, intermediate, high risk), 
overall by C-statistics, and by risk thresholds in terms of sensitivity, specificity, negative (NPV) and positive predictive values (PPV) 
for any bleeding at 2.5 year follow-up. 
Risk score C-statistics Threshold Sensitivity Specificity NPV PPV  
ATRIA 0.57 (0.56-0.58) Intermediate / high risk 26.8 87.9 96.6 8.7 
  High risk 14.9 93.3 96.2 8.7 
HAS-BLED 0.57 (0.56-0.58) Intermediate / high risk 60.6 53.8 97.0 5.3 
  High risk - - - - 
ORBIT 0.59 (0.58-0.60) Intermediate / high risk 32.7 84.4 96.7 8.2 
  High risk 18.9 91.9 96.4 9.1 
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